Oncolytics Biotech (ONCY) Free Cash Flow (2009 - 2024)
Oncolytics Biotech (ONCY) posted quarterly Free Cash Flow of $4295.1 for Q4 2024, up 94.91% year-over-year from $2203.6 in Q1 2024, and down 81.69% quarter-over-quarter from $23457.7 in Q3 2024.
Oncolytics Biotech (ONCY) Free Cash Flow (2009 - 2024) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Free Cash Flow for 16 consecutive years, with $4295.1 the latest figure, recorded in Q4 2024.
- In Q4 2024, Free Cash Flow rose 94.91% year-over-year to $4295.1; the TTM figure through Sep 2025 stood at $4295.1 (down 97.52% YoY), while the FY2025 annual figure was -$20.1 million, down 3.06% from the prior year.
- Free Cash Flow fell to $4295.1 in Q4 2024 per ONCY's latest filing, from $23457.7 in the prior quarter.
- Across five years, Free Cash Flow topped out at $162566.3 in Q3 2021 and bottomed at -$394475.3 in Q4 2021.
- Historically, Free Cash Flow has averaged $1171.6 across 5 years, with a median of $6900.7 in 2022.
- On a YoY basis, Free Cash Flow climbed as much as 1292.6% in 2021 and fell as far as 168513.99% in 2021.
- Oncolytics Biotech's Free Cash Flow stood at -$233.95 in 2020, then tumbled by 168513.99% to -$394475.3 in 2021, then jumped by 99.81% to -$736.7 in 2022, then soared by 399.12% to $2203.6 in 2023, then soared by 94.91% to $4295.1 in 2024.
- Business Quant data shows ONCY's Free Cash Flow at $4295.1 in Q4 2024, $23457.7 in Q3 2024, and $113326.8 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Oncolytics Biotech | 101.16 Mn | 101.16 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 4,295.09 |
| Dec 31, 2024 | 4,295.09 |
| Sep 30, 2024 | 23,457.71 |
| Sep 30, 2024 | 23,457.71 |
| Jun 30, 2024 | 113,326.78 |
| Jun 30, 2024 | 113,326.78 |
| Mar 31, 2024 | 34,137.21 |
| Mar 31, 2024 | 34,137.21 |
| Dec 31, 2023 | 2,203.61 |
| Dec 31, 2023 | 2,203.61 |
| Mar 31, 2023 | 3,698.48 |
| Mar 31, 2023 | 3,698.48 |
| Dec 31, 2022 | -736.70 |
| Dec 31, 2022 | -736.70 |
| Sep 30, 2022 | 6,900.72 |
| Sep 30, 2022 | 6,900.72 |
| Jun 30, 2022 | 9,133.65 |
| Jun 30, 2022 | 9,133.65 |
| Mar 31, 2022 | 28,421.11 |
| Mar 31, 2022 | 28,421.11 |